Navigation Links
Dendreon Announces Webcast Presentation at Credit Suisse 2010 Health Care Conference
Date:11/5/2010

SEATTLE, Nov. 5, 2010 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the Credit Suisse 2010 Health Care Conference, Phoenix, AZ on November 11, 2010 at 1:30 p.m. ET.

The presentation will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com.  If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE®, was approved by the FDA in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... May 26, 2015  Array BioPharma Inc. (Nasdaq: ... Executive Officer, Ron Squarer , will present ... New York City. The public is welcome to participate ... Array BioPharma website.Event: Jefferies 2015 Global Healthcare ConferencePresenter:Ron ... Eastern Time Webcast: www.arraybiopharma.com  About Array BioPharma ...
(Date:5/26/2015)... May 26, 2015 Sanomedics, Inc. (OTC: SIMH) ... has expanded into the fast growing behavioral health sector ... is a developmental stage, Software as a Services (SaaS) ... addiction treatment service and care centers. ... to enter the nascent behavioral health sector where the ...
(Date:5/26/2015)... , May 26, 2015 Boston Scientific Corporation ... Goldman Sachs 36 th Annual Global Healthcare Conference on ... Dan Brennan , executive vice president ... president, Investor Relations, will participate in a 35-minute question and ... at approximately 10 a.m. PT. A live webcast ...
Breaking Medicine Technology:Sanomedics Targeting Behavioral Health and Electronic Health Records with Strategic Acquisition of Zen Charts 2Sanomedics Targeting Behavioral Health and Electronic Health Records with Strategic Acquisition of Zen Charts 3Boston Scientific To Participate In The Goldman Sachs 36th Annual Global Healthcare Conference 2
... of once-daily TMC278 in ... treatment-naive adults with HIV-1 -, ... from Tibotec,Pharmaceuticals Ltd. provides additional information on the safety ... inhibitor (NNRTI), as part of HIV,combination therapy in treatment-naive ...
... CAMBRIDGE, Mass., Aug. 5 Tolerx, Inc., a,biopharmaceutical ... novel,therapies for the treatment of immune-mediated diseases, announced ... version of TRX1,MTRX1011A, an anti-CD4 monoclonal antibody, into ... patients. The clinical trial is evaluating the,safety and ...
Cached Medicine Technology:Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3
(Date:5/26/2015)... (PRWEB) May 26, 2015 It was ... community foundation in Colorado. On Wednesday, May 13, The ... in a new era of community-based giving with its ... “Our Future in the Making,” the event celebrated the ... Denver Foundation to mobilize resources for good. , “If ...
(Date:5/26/2015)... Synthetic cannabinoids attempt to mimic ... published by International Business Times on ... and black mamba) causes unpredictable medical and psychiatric ... make it nearly impossible for medical doctors to ... substance due to the frequency in which the ...
(Date:5/26/2015)... Norcross, GA (PRWEB) May 26, 2015 ... partnered with Airbus Defence and Space in a new ... data and software for use in the development of ... Hexagon Content Program, this partnership combines optical satellite data ... offerings. Intended to tear down the walls between geospatial ...
(Date:5/26/2015)... NY (PRWEB) May 26, 2015 Award-winning travel ... a good cause. "The photography show will connect viewers to ... their lives.” For the last five years, Raul has traveled ... convey the notion that we are not bounded by our ... language spoken in Raul’s native country, Bolivia. The photo gallery ...
(Date:5/26/2015)... 2015 On June 4, 2015, ... online broadcast at 6:00pm PST/9:00 pm EST. This ... Alice Branton welcomes the public to attend and invite ... profound knowledge, transformation and enlightenment. The webinar is ... previous knowledge, experience or other prerequisites are required. , ...
Breaking Medicine News(10 mins):Health News:Celebrating "Our Future in the Making" 2Health News:Celebrating "Our Future in the Making" 3Health News:Synthetic Cannabinoids Can Cause Psychotic Episodes; Doctors at a Loss for Treatment 2Health News:Synthetic Cannabinoids Can Cause Psychotic Episodes; Doctors at a Loss for Treatment 3Health News:Hexagon Geospatial and Airbus Defense Establish Partnership 2Health News:Hexagon Geospatial and Airbus Defense Establish Partnership 3Health News:A Photographer & Two Educational Organiazations Join to Make a Difference in Our Youth 2Health News:The Human Wellness Company Trivedi Master Wellness™ Opens a Complimentary Transformational Community Call to the Public on June 4, 2015 2Health News:The Human Wellness Company Trivedi Master Wellness™ Opens a Complimentary Transformational Community Call to the Public on June 4, 2015 3
... from eating fish to krill (shrimp-like marine invertebrate animals) ... and whales, ancient eggshell fragments reveal. ... Carolina in Wilmington, and William Patterson of the University ... removed krill-eating predators, the penguins exploited the resulting shrimp ...
... time, researchers have shown that plant growth is regulated ... ,Using time-lapse photography, post-doctoral researcher Kazunari Nozue, ... the University of Lausanne, Switzerland, found that the shoots ... a day. They claimed that the timing of that ...
... first after restoring the fertility of a woman made ... ,The gynaecologist, Jacques Donnez, said he had successfully ... at the Cliniques Universitaires Saint-Luc in Brussels. ... graft, the patient continues to menstruate regularly. Her ovarian ...
... the stone that kills two vices. ,United States FDA-approved smoking ... handed out to alcoholics as well . , The ... used quite successfully by smokers , was tested to reveal the ... ,Says Selena Bartlett, a University of California, San Francisco ...
... ESMO Conference Lugano this week show that the drug, ... a marker of cancer activity, and shrank tumors in ... also in patients who had previously been treated with ... have continued to grow despite medical or surgical castration, ...
... in the July issue of the journal Cancer Cell, ... in development of acute promyelocytic leukemia (APL) and identifies ... its variant forms. ,Results from two new ... events that cause a deadly type of leukemia.,APL is ...
Cached Medicine News:Health News:Penguins Altered Diet When Humans Began Hunting Whales and Seals 2Health News:Two In One Drug For Smokers And Drinkers 2Health News:Hormone Inhibitor in Prostate Cancer Treatment 2Health News:Insights into Acute Promyelocytic Leukemia 2Health News:Insights into Acute Promyelocytic Leukemia 3
Non-reflective black anodized aluminum. Selection of five pin hole sizes (0.8 mm to 1.5 mm). Overall length: 4.0 inches....
4 mm x 4 mm downward biting jaws, curved right, length of shaft 115 mm, overall length 9.3 inches....
Right side cutting....
20 mm. Plastic, methylmethacrylate. Supplied sterile....
Medicine Products: